Welcome and State of the Movement – George VradenburgView Session
Achieving Equity in Alzheimer's Disease
As Alzheimer’s therapies continue to make great progress, questions remain about how we can ensure equitable access to the right treatments, for the right patients, at the right time. What do we know--and not know--about the etiology of the disease in and the impact of new treatments on minoritized, and especially Black, populations? Key Question: How do we achieve success with such low rates of racial and ancestral diversity in clinical trials?
New Technologies for Early Detection and Diagnosis of Alzheimer’s
Scaling up technologies for early detection of Alzheimer’s pathology and cognitive impairment promises to transform the global response to Alzheimer’s disease. Digital biomarkers and fluid biomarkers (ranging from cerebrospinal fluid to blood) to detect the disease are advancing rapidly in clinical practice and will enable a more simple, timely, and accurate Alzheimer’s diagnosis. Key Question: What do these tools and technologies mean for patients and their doctors?
Alzheimer’s Symptoms and Care
The toolkit for treating people living with Alzheimer’s has grown significantly over the past few years, causing providers and health systems to adopt new care and treatment paradigms. This panel will look at high-quality care models and the role of symptomatic treatments for Alzheimer’s patients. Key Question: What should become the standard of care in 2024—and what should excellent care look like?